For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Tafamidis and Tafamidis meglumine represents a true change. These innovative therapies stabilize the transthyretin protein, preventing its harmful build-up and alleviating the impact of